IZALONTAMAB
UNII S8YH2C9NLA

Substance Identification & Data

This profile provides standardized clinical and technical data for Izalontamab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) S8YH2C9NLA.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2559704-24-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

S8YH2C9NLA

CAS Registry Number

2559704-24-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

IZALONTAMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C178396

National Cancer Institute reference terminology for clinical and research data.

INN ID

12022

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

MN-273

Identifier assigned by the United States Adopted Names Council.

Substance Type

Izalontamab

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Izalontamab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Izalontamab

Common Names & Synonyms

Anti-EGFR/HER3 Bispecific Antibody SI-B001

HER3 x EGFR SI-B001

IZALONTAMAB [USAN]

Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 γ1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), disulfide with human-mouse monoclonal C225 κ-chain, dimer

Immunoglobulin G1-scFv_L-kappa dimer, anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)] and anti-[Homo sapiens ERBB3 (receptor tyrosine protein kinase erbB-3, HER3)], monoclonal antibody, tetravalent, bispecific; G1-scFv fused chain (1-702) [gamma1 heavy chain anti-EGFR (1-448) [VH (Mus musculus IGHV2-2*03 (93.8%) -(IGHD) -IGHJ3*01 (92.9%) A128>S (119), CDR-IMGT [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo sapiens IGHG1*08p (100%), G1m3,1 (CH1 I103 (201), R120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)] -10-mer bis(tetraglycyl-seryl) linker (449-458) -scFv heavy-lambda anti-ERBB3 (459-702) [VH (Homo sapiens IGHV3-7*01 (91.8%) -(IGHD) -IGHJ2*01 (100%), CDR-IMGT [8.8.11] (484-491.509-516.555-565)) (459-576) -15-mer tris(tetraglycyl-seryl) linker (577-591) -V-LAMBDA (Homo sapiens IGLV2-14*03 (93.9%) -IGLJ2*01 (83.3%) L124>V (699), CDR-IMGT [9.3.11] (617-625.643-645.682-692)) (592-702)]], (222-214')-disulfide with kappa light chain anti-EGFR (1'-214') [V-KAPPA (Mus musculus IGKV5-48*01 (95.8%) -IGKJ5*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Izalontamab [WHO-DD]

izalontamab [INN]